- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | Belite Bio stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 16.10. | Belite Bio: ADR-Aktie markiert Rekordhoch bei 86,61 USD | 3 | Investing.com Deutsch | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 15.10. | Belite Bio: China NMPA Agrees To Accept NDA With Priority Review For Tinlarebant | - | RTTNews | ||
| 15.10. | Belite Bio, Inc: Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant | 118 | GlobeNewswire (Europe) | NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage... ► Artikel lesen | |
| 15.09. | Belite Bio: H.C. Wainwright senkt Kursziel auf 98 Dollar aufgrund erhöhter Aktienanzahl | 1 | Investing.com Deutsch | ||
| 12.09. | Belite Bio completes last subject visit in phase 3 Stargardt trial | 2 | Investing.com | ||
| 12.09. | Belite Bio, Inc: Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease | 294 | GlobeNewswire (Europe) | Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation... ► Artikel lesen | |
| 10.09. | Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE | 12 | Investing.com | ||
| 08.09. | Belite Bio sichert sich 125 Millionen Dollar durch Privatplatzierung für Augenmedikamente | 2 | Investing.com Deutsch | ||
| 08.09. | Belite Bio raises $125 million in private placement for eye disease drugs | 1 | Investing.com | ||
| 08.09. | Belite Bio, Inc: Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors | 1 | GlobeNewswire (USA) | ||
| 08.09. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.08. | Belite Bio auf H.C. Wainwright Konferenz: Strategischer Fokus auf Augenkrankheiten | 1 | Investing.com Deutsch | ||
| 12.08. | Belite Bio: Benchmark bekräftigt "Buy"-Rating und Kursziel von 80 US-Dollar | 1 | Investing.com Deutsch | ||
| 12.08. | Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target | 2 | Investing.com | ||
| 12.08. | Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress | 1 | Seeking Alpha | ||
| 12.08. | Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance | 1 | Investing.com | ||
| 11.08. | Belite Bio GAAP EPS of -$0.31 beats by $0.10 | 1 | Seeking Alpha | ||
| 11.08. | Belite Bio, Inc: Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | 302 | GlobeNewswire (Europe) | Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month... ► Artikel lesen | |
| 08.08. | Belite Bio's Earnings Outlook | 1 | Benzinga.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,560 | +2,85 % | Sangamo Therapeutics: Die Chance ist noch nicht vom Tisch! | ||
| ARGENX | 702,20 | -0,03 % | If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
| PROTALIX BIOTHERAPEUTICS | 1,860 | -7,92 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit Virtual | CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 5,720 | -2,47 % | Quanterix Corporation Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 9,230 | +2,56 % | Lexeo Therapeutics raises $153.8 million in public offering | ||
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 6,972 | +1,54 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 78,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.